Rawn Bosley, MD
Dermatology · Grapevine, TXNPI 1295027910
Payments from drug & device makers
Across 269 payments — averaging $126.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$15K
- Biofrontera Inc.$7K
- Galderma Laboratories, L.p.$4K
- AbbVie$3K
- Johnson & Johnson$699
- LEO Pharma Inc.$495
- plus $3K from 29 others
What the payments were for
- Consulting fees$5,91017%
- Speaking & faculty fees$14,32842%
- Food & beverage$6,67420%
- Education$2931%
- Other$6,75020%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 18 | $14,931 |
| Biofrontera Inc. | 11 | $7,390 |
| Galderma Laboratories, L.p. | 35 | $4,067 |
| AbbVie(2 entities) | 65 | $3,100 |
| Johnson & Johnson | 33 | $699 |
| LEO Pharma Inc. | 3 | $495 |
| Merz North America, Inc. | 3 | $477 |
| Kerecis Limited | 5 | $454 |
| Incyte Corporation | 17 | $419 |
| Lilly USA, LLC | 15 | $355 |
| Sun Pharmaceutical Industries Inc. | 15 | $269 |
| E.r. Squibb & Sons, L.L.C. | 3 | $170 |
| Gilead | 1 | $116 |
| Regeneron Healthcare Solutions, Inc. | 4 | $116 |
| Sanofi | 6 | $105 |
| Sage Therapeutics, LLC | 1 | $103 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 5 | $82 |
| Arcutis Biotherapeutics, Inc. | 3 | $64 |
| Revance Therapeutics, Inc. | 2 | $64 |
| Novartis | 2 | $57 |
| Almirall LLC | 3 | $57 |
| Amgen | 3 | $44 |
| Botanix SB Inc | 3 | $43 |
| Smith+Nephew | 2 | $41 |
| Regeneron | 1 | $38 |
| UCB, Inc. | 1 | $30 |
| Journey Medical Corporation | 1 | $26 |
| Springworks Therapeutics, Inc. | 1 | $26 |
| Fidia Pharma USA Inc. | 1 | $22 |
| LNHC, Inc | 1 | $19 |
| VYNE Pharmaceuticals Inc. | 1 | $19 |
| Bristol Myers Squibb | 1 | $17 |
| Sensus Healthcare, Inc. | 1 | $15 |
| Tempus AI, Inc | 1 | $15 |
| Mayne Pharma Commercial LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LITFULO$13,916
- AMELUZ$7,240
- BF-RhodoLED$7,240
- RhodoLED XL$6,750
- AKLIEF$1,000
- CIBINQO$831
- Kerecis Omega3 Marigen$588
- Kerecis SurgiClose$569
- ADBRY$450
- XEOMIN$250
- ASCLERA$250
- Kerecis Omega3 SurgiClose$147
- Kerecis GraftGuide$142
- XEPI$140
- Sotyktu$133
- BOTOX COSMETIC$124
- OPZELURA$121
- Truvada$116
- DYSPORT$110
How this compares
$33,955 in reported general payments places this provider in the 85th percentile of 1,098 dermatology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clobetasol Propionate | 33 | $1,729 |
| Fluocinonide | 15 | $410 |
| Triamcinolone Acetonide | 33 | $405 |
| Ammonium Lactate | 22 | $373 |
| Doxycycline Hyclate | 13 | $221 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Grapevine
- Stephen TyringWebster$14.1M
- Edward LainAustin$12M
- Mark LeeSan Antonio$10.9M
- John BrowningSan Antonio$10.7M
- Craig TellerBellaire$7.7M
- Patricia LeeWebster$7.2M
- Jennifer CatherDallas$4.9M
- Michael MigdenHouston$3.7M
- Martin MenterDallas$3.7M
- Janet DuboisAustin$3.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.